SRTS Form 4: Michael Sardano Increases Direct Holdings to 116,839 Shares

Rhea-AI Filing Summary

Michael Sardano, who serves as a director and as President and General Counsel of Sensus Healthcare, Inc. (SRTS), reported a purchase of 1,000 shares of the company's common stock on 08/13/2025 at a reported price of $3.37 per share. After the transaction, his reported direct beneficial ownership totaled 116,839 shares. The Form 4 lists the transaction code as "P" and shows the change as an acquisition.

Positive

• Insider acquisition reported: Michael Sardano acquired 1,000 shares of Sensus Healthcare common stock.
• Increased disclosed insider ownership: Reported direct beneficial ownership rose to 116,839 shares.

Negative

• None.

Insights

Securities Analyst

TL;DR: Officer purchase of 1,000 shares at $3.37 increased direct holdings to 116,839; transaction appears modest with limited market impact.

The Form 4 shows a non-derivative acquisition on 08/13/2025 where Michael Sardano purchased 1,000 common shares at $3.37, raising his direct beneficial ownership to 116,839 shares. The disclosure is straightforward and procedural; there is no additional information on plans or larger trading patterns in the filing to suggest material change in insider exposure.

Corporate Governance Expert

TL;DR: A director and executive reported a small direct purchase; it increases disclosed insider ownership but is not a material shift.

The filing identifies Sardano as both a director and as President and General Counsel and documents a purchase recorded under transaction code "P." The report updates public records of insider holdings to 116,839 shares. The filing provides clear compliance with Section 16 reporting requirements but contains no governance actions or changes in role.

Insider Trade Summary

Net Buyer: 1,000 shares ($3,370)

Net Buy 1 txn

Insider Sardano Michael

Role PRESIDENT AND GENERAL COUNSEL

Bought 1,000 shs ($3K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,000	$3.37	$3K

Holdings After Transaction: Common Stock — 116,839 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sardano Michael

(Last) (First) (Middle)

851 BROKEN SOUND PARKWAY NW

STE. 215

(Street)

BOCA RATON FL 33487

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sensus Healthcare, Inc. [ SRTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND GENERAL COUNSEL

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		P		1,000	A	$3.37	116,839	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Michael Sardano	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for SRTS?

Michael Sardano, identified as a director and as President and General Counsel of Sensus Healthcare, Inc.

What transaction was reported on the Form 4 for SRTS?

A non-derivative acquisition of 1,000 shares of common stock reported on 08/13/2025.

At what price did the insider transaction for SRTS occur?

The reported price was $3.37 per share.

How many SRTS shares does the reporting person own after the transaction?

The filing reports 116,839 shares beneficially owned following the reported transaction.

What does the transaction code on the Form 4 indicate?

The Form 4 shows transaction code "P" in the table for the reported acquisition.